ImmuneFDA clears IND for Ribox’s RXIM-002 for autoimmune cytopeniasRibox Therapeutics Ltd. has obtained IND clearance from the FDA for RXIM-002, a circular RNA (circRNA)-based in vivo CAR-T therapy delivered by a targeted lipid nanoparticle (tLNP). The company will conduct a phase I trial in patients with autoimmune cytopenias, including patients with relapsed or refractory immune thrombocytopenia.